Our Commitment - Relentless CRO Collaborators

When you unite proven ideas with novel concepts you expect to experience results. At Covance, we draw on our extensive background and couple that with constant innovation to shape new solutions for you. With Covance as your partner, you’ll benefit from our integrated development processes and will experience why Covance received the highest score in both preclinical and clinical quality*.

Optimizing study designs can be challenging and often overlooked. Covance knows a unique, unbiased perspective can help. We can optimize your design to create savings — without compromising quality, delivery or regulatory acceptance. 

We are driven to offer unique services to move your molecule development forward. It’s just a few of the unique attributes that prompt clients to cite Covance as the contract research organization that’s “best positioned” for discovery, preclinical and clinical work**.

Maintaining lasting client relationships is more than delivering results. We hold ourselves to high standards of integrity to support the service excellence that you expect. At Covance, we’ve built a foundation of values centered on corporate stewardship through strong governance, responsible use of company resources and active involvement in our local communities. See how this combination of ethics and social responsibility preserve confidence with our clients and within our global communities. 

Learn more about our Business Integrity Program

Find out about our corporate social responsibility commitment

We aim to make each and every client project a success. That’s the foundation of our growth and prosperity — operational and service excellence. By continually enhancing client satisfaction, we make sure you have the best possible outcome. Collaborate with us and you’ll understand why Covance was named the clear favorite contract research organization to work with***.

Team members shake hands to kick off a CRO collaboration at Covance.

*Morgan Stanley Research North America, 3-Mar-2013
**Baird Equity Research report, 2013
***Baird Equity Research, 2-Apr-2013